Available Technology

Treatment of Pulmonary Fibrosis using NEU1 Salidase Inhibitors

The present invention provides a method for treating a fibrotic lung disease or fibrotic lung condition in a subject that involves an increase in NEU1 expression and/or activity, by administering to the patient an effective amount of an agent that inhibits the activity of neuraminidase-1 (NEU-1) sialidase. The agent could be a small-molecule chemical and/or a biologic compound that inhibit NEU-1 sialidase. These chemicals and/or biologic compounds are used to treat or prevent Idiopathic Pulmonary Fibrosis and other fibrotic lung diseases and conditions in a patient. For example, the NEU-1 sialidase inhibitors can also treat sarcoidosis, allergic pneumonia, pneumoconiosis, drug-induced fibrosis, radiation-induced fibrosis, noxious chemical compound-induced fibrosis, and fibrogenic alveolitis associated with collagen vascular disease.

Patent Abstract: 

The present invention provides a method for treating a fibrotic lung disease or fibrotic lung condition in a subject that involves an increase in NEU1 expression and/or activity, by administering to the patient an effective amount of an agent that inhibits the activity of neuraminidase-1 (NEU-1) sialidase. The agent could be a small-molecule chemical and/or a biologic compound that inhibit NEU-1 sialidase. These chemicals and/or biologic compounds are used to treat or prevent Idiopathic Pulmonary Fibrosis and other fibrotic lung diseases and conditions in a patient. For example, the NEU-1 sialidase inhibitors can also treat sarcoidosis, allergic pneumonia, pneumoconiosis, drug-induced fibrosis, radiation-induced fibrosis, noxious chemical compound-induced fibrosis, and fibrogenic alveolitis associated with collagen vascular disease.

Benefits 

Reducing and/or preventing lung fibrosis

Reps: 
Inventors: 

Sergei P Atamas, Irina Luzina, and Simeon E Goldblum

Patent Number: 
WO 2021-007329
Reference Code: 
VA ID 2019-175
Technology Type(s): 
Small molecule chemical and/or biologic agent to treat lung disease, pulmonary fibrosis in particular
Internal Laboratory Ref #: 
VA ID 2019-175
Patent Status: 
PCT patent application PCT/US2020/041212 was filed July 8, 2020 and published as WO 2021-007329 on January 14, 2021
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin